|1.||Atassi, Ghanem: 1 article (08/2002)|
|2.||Guillonneau, Claude: 1 article (08/2002)|
|3.||Kraus-Berthier, Laurence: 1 article (08/2002)|
|4.||Guilbaud, Nicolas: 1 article (08/2002)|
|5.||Léonce, Stéphane: 1 article (08/2002)|
|6.||Parker, Tracy: 1 article (08/2002)|
|7.||Genissel, Patrick: 1 article (08/2002)|
|8.||Pierré, Alain: 1 article (08/2002)|
|9.||Goldstein, Solo: 1 article (08/2002)|
|1.||Lewis Lung Carcinoma
08/01/2002 - "Although tumor cell proliferation and accumulation of cells in the G2 phase of the cell cycle were similarly affected by the two compounds after a continuous exposure (IC50 values of 30-50 n M), S 30972-1 was about tenfold less potent than S 16020-2 after short exposures. "
08/01/2002 - "To compare the pharmacological profile of S 30972-1 and S 16020-2 in vitro and in vivo and to investigate whether S 30972-1 could act as a prodrug of S 16020-2. The two compounds were compared in vitro in terms of their activity in inhibiting cellular proliferation and perturbing the cell cycle and in vivo in terms of their antitumor activity in murine transplantable tumors and human orthotopic models. "